Effectiveness of antihypertensive agents in stage I/II hypertensive patients with ace (I/D) gene polymorphism

Bansal G, Chaithanya TM, Alam MA, Manchi RK

Pdf Page Numbers :- 22-25

Garima Bansal¹, Thota Madhu Chaithanya², Md Amir Alam³, and Rajesh Kumar Manchi^4,*

¹Department of Pharmacology, Pacific Medical College and Hospital, Pratappura, Udaipur- 313001, Rajasthan, India

²Department of Pharmacology, Saraswati Medical College, Madhuvihar, Ashakhera, Unnao, Uttar Pradesh-209859, India

³Department of Pharmacology, RKDF Medical College Hospital & Research Center & Hospital, Bhopal-462026, Madhya Pradesh, India

⁴Department of Pharmacology, Lord Buddha Koshi Medical College & Hospital, Baijnathpur, Saharsa - 852221, Bihar, India

*Corresponding author: Dr. Rajesh Kumar Manchi, Associate Professor, Department of Pharmacology, Saraswati Medical College, Madhuvihar, Ashakhera, Unnao, Uttar Pradesh-209859, India. Email: manchirajesh1985@gmail.com

Received 21 September 2022; Revised 19 November 2022; Accepted 2 December 2022; Published 12 December 2022

Citation: Bansal G, Chaithanya TM, Alam MA, Manchi RK. Effectiveness of antihypertensive agents in stage I/II hypertensive patients with ace (I/D) gene polymorphism. J Med Sci Res. 2023; 11(1):22-25. DOI: http://dx.doi.org/10.17727/JMSR.2023/11-5

Copyright: © 2023 Bansal G et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PDF

Abstract

Background: Angiotensin converting enzyme (ACE) is the key enzyme, regulates the blood pressure which is encoded by 21kb gene that consists of 26 exons and is located on chromosome 17, contains a polymorphism in the form of either Insertion (I) or Deletion (D). The aim was to study the effect of antihypertensive drugs in patients of essential hypertension associated with ACE gene polymorphism.

Methods: Hypertensive patients were recruited followed by genetic test was done for detecting ACE gene polymorphism, then patients were divided as Group-A & B. Group –A and B patients were treated with atenolol (25mg) and azilsartan (40 mg) for three months respectively.

Results: Systolic and diastolic blood pressure was recorded in both the groups before and after commencement of treatment. Among 88 patients of newly diagnosed hypertension, majority of study population belongs to genotype D/D (38.63%) followed by I/D (31.81%) and II (29.54%) genotype. Significant difference was found in systolic blood pressure (p<0.05) of both groups but not diastolic blood pressure (p>0.05).

Conclusion: The rate of control of blood pressure was high in I/I genotype followed by D/D genotype irrespective of treatment group. Overall better prognosis was observed with azilsartan 40mg compared to atenolol 25mg treatment in patients with ACE gene polymorphisms.

Keywords: hypertension; ACE gene; azilsartan; atenolol; pharmacogenetics